News

Serodus ApS Appoints New Chief Executive Officer to Lead Strategic Divestment of Assets

Copenhagen — September 17, 2026 — Serodus ApS, a biotechnology company focused on the development of innovative anti-inflammatory compounds, today announced the appointment of Lars Smedegaard Andersen as Chief Executive Officer, effective as of today.

Read the full press release here

• Serodus ApS has received additional SER130 pharmacological results.
• The General Annual Meeting was held in Oslo on 9th June 2026 and the Annual Report 2025 was approved without comments.

Read more here

Download the minutes here

Serodus AS – Publishes 2025 Annual Report

Download it here

Download notice here

• Serodus ApS has received additional SER130 pharmacological results.

Read more here

The company will hold a shareholder meeting in Copenhagen on 8th April from 16.00 at the premises of Elmann Advokater, Stockholmsgade 41, DK-2100 Copenhagen Ø.

The meeting language will be Danish.

Please register for participation at post@serodus.com.

• Serodus ApS will receive additional pharmacological reports from last studies with SER130.
• Shareholder meeting will be held in Q1 or Q2 2026

Read more here

• Serodus ApS will receive final pharmacological reports from last studies with SER130.
• Shareholder meeting will be held in Q1 2026.

Read more here

• Serodus ApS has initiated sale of SER150.
• Serodus ApS will finalize the pharmacological studies of SER130.

Read more here